Sector: Healthcare | Industry: Pharmaceuticals |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 102 WOODMONT BLVD, SUITE 610 NASHVILLE TN 37215 |
Tel: | N/A |
Website: | https://www.harrow.com |
IR: | See website |
Key People | ||
Mark L. Baum Chairman of the Board, Chief Executive Officer | Andrew R. Boll Chief Financial Officer, Corporate Secretary | John P. Saharek President and Chief Executive Officer of ImprimisRx, Chief Commercial Officer |
Business Overview |
Harrow, Inc. is an eyecare pharmaceutical company. The Company is engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the United States market. It provides a comprehensive portfolio of prescription and non-prescription pharmaceutical products. It owns commercial rights to portfolios of branded ophthalmic pharmaceutical products in North America, all of which are marketed under the Harrow name. It owns and operates ImprimisRx, an ophthalmology-focused pharmaceutical-compounding business. It owns United States commercial rights to various products: IHEEZO, VEVYE, TRIESENCE, VIGAMOX, ILEVRO, FLAREX, NATACYN, ZERVIATE and others. VIGAMOX (moxifloxacin hydrochloride ophthalmic solution) 0.5%, a fluoroquinolone antibiotic eye drops for the treatment of bacterial conjunctivitis caused by susceptible strains of organisms. IHEEZO (chloroprocaine hydrochloride ophthalmic gel) 3% is a low-viscosity gel indicated for ocular surface anesthesia. |
Financial Overview |
For the fiscal year ended 31 December 2023, Harrow Inc revenues increased 47% to $130.2M. Net loss increased 73% to $24.4M. Revenues reflect Product Sales Net segment increase of 41% to $117.4M. Higher net loss reflects Selling, general and administrative increase of 35% to $66.2M (expense), Interest expense increase from $7.2M to $21.3M (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$0.51 to -$0.75. |
Employees: | 315 as of Mar 1, 2024 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $484.09M as of Dec 31, 2023 |
Annual revenue (TTM): | $130.19M as of Dec 31, 2023 |
EBITDA (TTM): | $12.42M as of Dec 31, 2023 |
Net annual income (TTM): | -$24.41M as of Dec 31, 2023 |
Free cash flow (TTM): | -$148.70M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | $100.41M as of Dec 31, 2023 |
Shares outstanding: | 35,362,642 as of Mar 18, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |